Collectively, these data demonstrate the development of an integrated antitumor immune response mediated by a combination of chidamide/anti-PD1 and suggest that the underlying mechanism involves immune cell trafficking, infiltration, and killing of cancer cells. Here, PDCD1 is linked to cancer.